“So we will soon be going into safety expansion cohort. And at that point, we will establish what degree of efficacy we're seeing in a defined patient population, and that'll help us decide towards the end of this year where we're going from a phase two perspective.”
→ Read the source episode
StepPharma announces transition of lymphoma trial to safety expansion cohort and reports phase two advancement decision by 2026-12-31
Andy Parker predicts ET trial will recruit 50 patients by summer 2027 and be phase three ready by end of 2027.
Andy Parker predicts StepPharma will complete ET phase two by end of 2027 and begin planning phase three.
Andy Parker predicts StepPharma will raise additional funding within next six months (by January 2027).
Andy Parker predicts phase one readout from solid tumor safety expansion cohorts within 12-15 months (by October 2027).
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.